While the strategy might result in high prices, it isn't illegal, a judge wrote in siding with AbbVie. "AbbVie has exploited advantages conferred on it through lawful practices and to the extent this has kept prices high for Humira, existing antitrust doctrine does not prohibit it," U.S. District Judge Manish Shah wrote in an order dismissing the plaintiffs' lawsuit. I-MAK in 2018 found AbbVie filed 247 patent applications for Humira and won patents that could have protected the medicine for up to 39 years. The drug's price jumped 144% since 2012.